natgillin/translations-raw huggingface dataset:
• Your doctor will check your blood pressure before and during your MIRCERA treatment.
· Zdravnik vam bo preverjal krvni tlak pred in med zdravljenjem z zdravilom MIRCERA.
Place a sterile cotton ball or gauze over the injection site and press for several seconds.
Postavite sterilno vato ali gazo na mesto injiciranja in pritisnite za nekaj sekund.
MIRCERA is indicated to treat only the symptomatic anaemia caused by chronic kidney disease.
Zdravilo MIRCERA uporabljamo le za zdravljenje simptomatske anemije, ki jo povzroča kronična ledvična bolezen.
Your doctor will check that you do not have other causes of anaemia and may perform blood tests or examine your bone marrow.
Zdravnik bo preveril, če obstaja drug vzrok anemije, morda vas bo napotil na preiskave krvi ali kostnega mozga.
IMPORTANT INFORMATION · Only use MIRCERA pre-filled syringeif you have been prescribed with this · medication.
POMEMBNE INFORMACIJE · Uporabljajte le napolnjeno injekcijsko brizgo zdravila MIRCERA, ki vam je bila predpisana.
Store the syringe in its original box until ready to use.
Injekcijsko brizgo shranjujte v originalni ovojnini, dokler ni pripravljena za uporabo.
It is unknown whether MIRCERA is excreted in human breast milk.
Ni znano, če zdravilo MIRCERA prehaja v materino mleko.
If your blood pressure is high and cannot be controlled, either by appropriate medicines or a special diet, your doctor will interrupt your MIRCERA treatment or reduce the dose.
Če bo krvni tlak visok in ga ne bo mogoče uravnati z ustreznimi zdravili ali dieto, bo zdravnik zdravljenje z zdravilom MIRCERA prekinil ali pa bo zmanjšal njegov odmerek.
· Not allowing the medicine to come to room temperature could result in an uncomfortable injection, and it may be difficult to depress the plunger.
· Če se zdravilo ne bo segrelo na sobno temperaturo, lahko pride do neprijetnega injiciranja in težav pri sproščanju bata.
Intravenous route:
Intravenska pot:
The safety data base from clinical trials comprised 3,042 CKD patients, including 1,939 patients treated with MIRCERA and 1,103 with another ESA.
Podatke o varnosti v kliničnih preskušanjih so pridobili pri 3.042 bolnikih s kronično ledvično boleznijo; od tega jih je bilo 1.939 zdravljenih z zdravilom MIRCERA, 1.103 pa z drugimi zdravili, ki spodbujajo eritropoezo.
Perform the injection
KAKO SI DATI INJEKCIJO
Due to intra-patient variability, occasional individual haemoglobin values for a patient above and below the desired haemoglobin level may be observed.
Zaradi variabilnosti med bolniki lahko občasno opazimo, da je koncentracija hemoglobina posameznega bolnika nad ali pod želeno.
A comparison of serum concentrations of methoxy polyethylene glycol-epoetin beta measured before and after haemodialysis in 41 CKD patients showed that haemodialysis has no effect on the pharmacokinetics of this medicinal product.
Primerjava serumskih koncentracij metoksipolietilenglikol epoetina beta, ki so jih izmerili pred hemodializo in po njej pri 41 bolnikih s kronično ledvično boleznijo, je pokazala, da hemodializa na farmakokinetiko tega zdravila ne vpliva.
Other medicines and MIRCERA
Druga zdravila in zdravilo MIRCERA
• Your doctor may initiate treatment with MIRCERA if your haemoglobin level is 10 g/dl (6.21 mmol/l) or less.
· Vaš zdravnik lahko uvede zdravljenje z zdravilom MIRCERA, če je vaša koncentracija hemoglobina 10 g/dl (6,21 mmol/l) ali manj.
A decision on whether to continue or discontinue breast-feeding or to continue or discontinue therapy with MIRCERA should be made taking into account the benefit of breast-feeding to the child and the benefit of MIRCERA therapy to the woman.
Pri odločitvi o nadaljevanju ali ukinitvi zdravljenja z zdravilom MIRCERA je treba presoditi glede na koristi dojenja za otroka in koristi zdravljenja z zdravilom MIRCERA za mater.
Physicians may request the Marketing Authorisation Holder to test or re-test serum samples in a reference laboratory for cases of suspected or confirmed AEAB-mediated PRCA or unexplained loss of effect under MIRCERA treatment (e.g. observed clinically by severe anaemia and low reticulocyte count).
Zdravniki lahko od imetnika dovoljenja za promet z zdravilom zahtevajo testiranje ali ponovno testiranje vzorcev seruma v referenčnem laboratoriju za primere suma ali potrjene čiste aplazije rdečih krvnih celic, povzročene s protitelesi proti eritropoetinu, ali nepojasnjene izgube učinka pri zdravljenju z zdravilom MIRCERA (npr. klinično opaženo kot huda anemija in majhno število retikulocitov).
If the amount is too low your doctor may give you an additional iron supplement.
Če bo koncentracija premajhna, vam lahko predpiše dodatno zdravljenje z železovim pripravkom.
Remove the box containing the MIRCERA pre-filled syringe from the refrigerator.
Škatlo, ki vsebuje napolnjeno injekcijsko brizgo zdravila MIRCERA, vzemite iz hladilnika.
A patient-level data analysis has also been performed on more than 13,900 cancer patients (chemo-, radia-, chemoradia-, or no therapy) participating in 53 controlled clinical trials involving several epoetins.
Pri več kot 13.900 bolnikih z rakom (na kemoterapiji, radioterapiji, kemoradioterapiji ali brez terapije), ki so sodelovali v 53 nadzorovanih kliničnih preskušanjih, ki vključujejo več epoetinov, so izvedli tudi analizo podatkov na nivoju posameznega bolnika.
After initiation of therapy, your doctor will seek to maintain your haemoglobin level between 10 and 12 g/dl (7.45 mmol/l).
Po začetku zdravljenja bo zdravnik skušal vzdrževati vašo koncentracijo hemoglobina med 10 in 12 g/dl (7,45 mmol/l).
METHOD AND ROUTE(S) OF ADMINISTRATION For subcutaneous or intravenous use Read the package leaflet before use
POSTOPEK IN POT(I) UPORABE ZDRAVILA Za subkutano ali intravensko uporabo Pred uporabo preberite priloženo navodilo
After dose interruption a haemoglobin decrease of approximately 0.35 g/dl (0.22 mmol/l) per week is expected.
Po prekinitvi dajanja je pričakovani padec koncentracije hemoglobina približno 0,35 g/dl (0,22 mmol/l) na teden.
Your doctor will carry out regular blood tests to monitor how your anaemia is responding to treatment by measuring your haemoglobin level.
Zdravnik vas bo redno napotil na krvne preiskave (merjenje koncentracije hemoglobina), da bo spremljal, kako se vaša anemija odziva na zdravljenje.
Driving and using machines MIRCERA does not affect your ability to drive and use machines.
Vpliv na sposobnost upravljanja vozil in strojev Zdravilo MIRCERA ne vpliva na vašo sposobnost upravljanja vozil in strojev.
The strength indicates the quantity of the protein moiety of the methoxy polyethylene glycol-epoetin beta molecule without consideration of the glycosylation.
Jakost se nanaša na vsebnost proteinskega dela molekule metoksipolietilenglikol epoetina beta brez upoštevanja glikozilacije.
• If you are a patient with hepatitis C and you receive interferon and ribavirin you should discuss this with your doctor because a combination of ESAs with interferon and ribavirin has lead to a loss of effect and development of PRCA, a severe form of anemia, in rare cases.
· Če imate hepatitis C in prejemate interferon ter ribavirin se morate o tem pogovoriti z zdravnikom, saj kombinacija zdravil za spodbujanje eritropoeze z interferonom in ribavirinom lahko v redkih primerih privede do izgube učinka in razvoja čiste aplazije rdečih krvnih celic,
Do not release the plunger before the end of injection or before the plunger is completely depressed.
Bata ne sprostite do konca injiciranja oziroma dokler bat ni pritisnjen do konca.
When MIRCERA was administered subcutaneously to male and female rats prior to and during mating, reproductive performance, fertility, and sperm assessment parameters were not affected.
Ko so zdravilo MIRCERA dajali subkutano podganjim samcem in samicam pred parjenjem in po njem, ni bilo vpliva na ocenjevane parametre za sposobnost razmnoževanja, plodnost in seme.
· Do not touch the release clips of the safety device.
· Ne dotikajte se sprostitvenih sponk na varnostnem pripomočku.
Patients should be monitored closely to ensure that the lowest approved effective dose of MIRCERA is used to provide adequate control of the symptoms of anaemia whilst maintaining a haemoglobin concentration below or at 12 g/dl (7.45 mmol/l).
Bolnike je treba pozorno spremljati, da lahko z najmanjšim odobrenim učinkovitim odmerkom zdravila Mircera simptome anemije ustrezno nadzorujemo in hkrati vzdržujemo koncentracijo hemoglobina pod 12 g/dl (7,45 mmol/l) ali na tej vrednosti.
· The contents are cloudy, hazy or contain particles.
· je vsebina motna ali vsebuje vidne delce.
In case of excessive haemoglobin levels, treatment with MIRCERA should be temporarily discontinued (see section 4.2).
Kadar so koncentracije hemoglobina prevelike, je treba zdravljenje z zdravilom MIRCERA začasno prekiniti (glejte poglavje 4.2).
If your healthcare professional has recommended injection of MIRCERA into a vein, you should follow the procedure described below.
Če vam je zdravnik svetoval dajanje zdravila MIRCERA v veno, sledite spodaj opisanemu postopku.
If all the conditions mentioned are excluded and the patient has a sudden drop of haemoglobin associated with reticulocytopenia and anti-erythropoietin antibodies, examination of the bone marrow for the diagnosis of Pure Red Cell Aplasia (PRCA) should be considered.
Če ste izključili vsa omenjena stanja in se pri bolniku pojavi nenaden padec koncentracije hemoglobina, povezan z retikulocitopenijo in protitelesi proti eritropoetinu, pride v poštev pregled kostnega mozga zaradi možne diagnoze čiste aplazije rdečih celic.
· Do not use the pre-filled syringe if syringe, or the plastic tray containing the syringe appears to be damaged.
· Ne uporabljajte napolnjene injekcijske brizge, če je napolnjena injekcijska brizga ali plastičen omot, ki jo vsebuje, poškodovan.
• If you get any side effects, talk to your doctor.
· Če opazite kateri koli neželeni učinek, se posvetujte z zdravnikom.
The absolute bioavailability of methoxy polyethylene glycol-epoetin beta after subcutaneous administration was 62% and the observed terminal elimination half-life was 139 hours in CKD patients on dialysis.
Absolutna biološka uporabnost metoksipolietilenglikol epoetina beta po subkutanem dajanju je bila 62 %, ugotovljeni končni razpolovni čas izločanja pri dializnih bolnikih s kronično ledvično boleznijo pa 139 ur.
This medicinal product contains less than 1 mmol sodium (23 mg) per ml, i.e. essentialy sodium free.
To zdravilo vsebuje manj kot 1 mmol (23 mg) natrija na ml, kar v bistvu pomeni brez natrija.
Subcutaneous use is preferable in patients who are not receiving haemodialysis to avoid puncture of peripheral veins.
Pri bolnikih, ki niso na dializi, dajemo prednost subkutanemu dajanju, saj se tako izognemo punkciji perifernih ven.
Pre-filled syringe (type I glass) with laminated plunger stopper (bromobutyl rubber) and tip cap (bromobutyl rubber) and a needle 27G1/2.
Napolnjena injekcijska brizga (steklo tip I) z laminiranim zamaškom in batom iz brombutilne gume in pokrovom na vrhu (iz brombutilne gume) ter iglo 27G1/2.
The solution is clear, colourless to slightly yellowish and free of visible particles.
Raztopina je bistra, brezbarvna do rahlo rumenkasta in brez vidnih delcev.
In clinical trials, an increased risk of death, serious cardiovascular events including thrombosis or cerebrovascular events including stroke was observed when ESAs were administered to target a haemoglobin of greater than 12 g/dl (7.5 mmol/l) (see section 4.8).
V kliničnih preskušanjih so opazili povečano tveganje za smrt in resne srčnožilne dogodke, vključno s trombozo ali cerebrovaskularne dogodke, vključno s kapjo, če je bila ciljna koncentracija hemoglobina dosežena z zdravili za stimulacijo eritropoeze (ESA) nad 12 g/dl (7,5 mmol/l) (glejte poglavje 4.8).
Table 1: MIRCERA starting doses Previous weekly darbepoetin alfa intravenous or subcutaneous dose (microgram/week)
Preglednica 1: Uvajalni odmerki zdravila MIRCERA Prejšnji tedenski odmerek darbepoetina alfa, dan intravensko ali subkutano (mikrogram/teden)
Dose changes will not be made more often than once a month.
Odmerka ne bo spreminjal več kot enkrat na mesec.
If you use more MIRCERA than you should
MIRCERA, kot bi smeli.
There was however a class-related reversible reduction in foetal weight and a decrease in postnatal body-weight gain of offspring at the doses causing exaggerated pharmacodynamic effects in mothers.
Prišlo pa je do reverzibilnega zmanjšanja mase zarodka, ki je značilno za to skupino zdravil in do upada postnatalnega prirasta telesne mase potomcev ob odmerkih, ki so pri samicah povzročili pretirano farmakološko delovanje.
Grasp the syringe and the rubber tip cap firmly and remove the rubber tip cap from the syringe (bend and pull).
Trdno primite injekcijsko brizgo in gumijasti pokrovček ter odstranite gumijasti pokrovček z injekcijske brizge (upognite in povlecite).
MIRCERA has not been studied in pregnant or breast-feeding women.
Zdravila MIRCERA niso raziskali pri nosečnicah ali doječih materah.
Previous weekly epoetin intravenous or subcutaneous dose (IU/week)
Prejšnji tedenski odmerek epoetina, dan intravensko ali subkutano (i.e./teden)
· Do not push the plunger.
· Ne potegujte bata.
Monthly MIRCERA intravenous or subcutaneous dose (microgram/once monthly)
Mesečni odmerek zdravila MIRCERA, dan intravensko ali subkutano (mikrogram/enkrat na mesec)
SJS/TEN can appear initially as reddish target-like spots or circular patches often with central blisters on the trunk.
SJS/TEN se lahko pojavita kot rdečkaste, tarčam podobne makule ali okrogle lise po telesu, pogosto z mehurjem na sredini.
A rise in haemoglobin of greater than 2 g/dl (1.24 mmol/l) over a four-week period should be avoided.
Povečanju koncentracije hemoglobina za več kot 2 g/dl (1,24 mmol/l) v štirih tednih se je treba izogibati.
In responding to hypoxia, the natural hormone erythropoietin interacts with erythroid progenitor cells to increase red cell production.
V odgovoru na hipoksijo pride do interakcije med naravnim hormonom eritropoetinom in progenitornimi matičnimi celicami za eritrocite, kar poveča tvorbo rdečih krvnih celic.
The dose is to be administered once every two weeks as a single injection under the skin or into a vein.
Odmerek boste dobili enkrat na dva tedna kot eno injekcijo pod kožo ali v veno.
Effect on tumour growth: MIRCERA, like other ESAs, is a growth factor that primarily stimulates red blood cell production.
Vpliv na rast tumorja: Tudi MIRCERA je kot druga zdravila, ki spodbujajo eritropoezo, rastni dejavnik, ki primarno spodbuja nastajanje rdečih krvnih celic.
In a single dose study, after intravenous administration, the pharmacokinetics of methoxy polyethylene glycol-epoetin beta are similar in patients with severe hepatic impairment as compared to healthy subjects (see section 4.2).
V študiji enkratnega odmerjanja je bila po intravenskem dajanju zdravila farmakokinetika metoksipolietilenglikol epoetina beta pri bolnikih s hudo jetrno okvaro podobna tisti pri zdravih osebah (glejte poglavje 4.2).
If you miss a dose of MIRCERA administer the missed dose as soon as you remember and talk to your doctor about when to use the next doses.
Če ste pozabili uporabiti zdravilo MIRCERA Če ste izpustili odmerek zdravila MIRCERA, si izpuščeni odmerek injicirajte takoj, ko se spomnite, in se pogovorite z zdravnikom o tem, kdaj naj uporabite naslednje odmerke.
One animal study has shown excretion of methoxy polyethylene glycol-epoetin beta in maternal milk.
V eni študiji na živalih so pokazali izločanje metoksipolietilenglikol epoetina beta v mleko samic.
PRCA in patients with Hepatitis C: A paradoxical decrease in haemoglobin and development of severe anaemia associated with low reticulocyte counts should prompt to discontinue treatment with epoetin and perform anti-erythropoietin antibody testing.
Čista aplazija rdečih krvnih celic pri bolnikih s hepatitisom C: Paradoksno znižanje vrednosti hemoglobina in razvoj hude anemije povezane z nizkim številom retikulocitov zahteva takojšnjo prekinitev zdravljenja z epoetinom in testiranje na protitelesa proti eritropoetinu.
· Do not use the syringe if the contents are cloudy, hazy or contain particles.
· Ne uporabljajte injekcijske brizge, če je njena vsebina motna ali vsebuje delce.
· Be sure not to touch the cleaned area prior to the injection and do not fan or blow on the clean area.
· Ne dotikajte se očiščene površine pred injiciranjem ter ne pihajte nanjo.
Wipe off the venous port of the hemodialysis as instructed by your healthcare provider
Očistite venski dostop pri hemodializni krvni liniji, kot vam je naročil zdravstveni delavec.
If you develop a serious rash or another of these skin symptoms stop taking Mircera and contact your doctor or seek medical attention immediately.
Če se pojavi hud izpuščaj ali drugi kožni simptomi, prenehajte uporabljati zdravilo Mircera in nemudoma obvestite zdravnika ali poiščite zdravniško pomoč.
Release the plunger, allowing the needle guard to protect the needle.
Sprostite bat in s tem bo varovalo za iglo zaščitilo iglo.
MIRCERA can be injected under the skin in the abdomen, arm or thigh; or into a vein.
Zdravilo MIRCERA lahko injiciramo pod kožo v trebuh, roko ali stegno ali pa v veno.
Insert the needle of the pre-filled syringe into the cleaned venous port.
Vstavite iglo napolnjene injekcijske brizge v očiščen venski dostop.
The pharmacokinetics of methoxy polyethylene glycol-epoetin beta were studied in healthy volunteers and in anaemic patients with CKD including patients on dialysis and not on dialysis.
Farmakokinetiko metoksipolietilenglikol epoetina beta so raziskali pri zdravih prostovoljcih in anemičnih bolnikih s kronično ledvično boleznijo, ki so bili na dializi ali pa ne.
MIRCERA is not recommended for use in children and adolescents below 18 years due to a lack of safety and efficacy data.
Zaradi pomanjkanja podatkov o varnosti in učinkovitosti uporaba zdravila MIRCERA pri otrocih in mladostnikih, mlajših od 18 let, ni priporočljiva.
Do not use this medicine after the expiry date which is stated on the outer carton and pre-filled syringe label after ‘EXP'.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in napolnjeni injekcijski brizgi poleg oznake EXP. Rok uporabnosti zdravila se izteče na zadnji dan navedenega meseca.
No adjustments of the starting dose nor of the dose modification rules are required in patients with hepatic impairment (see section 5.2).
Pri bolnikih z okvaro jeter začetnega odmerka ali smernic za prilagajanje odmerkov ni potrebno spreminjati (glejte poglavje 5.2).
This includes any possible side effects not listed in this leaflet.
Posvetujte se tudi, če opazite katere koli neželeni učinke, ki niso navedeni v tem navodilu.
It did not induce a proliferative response in non-haematological tumor cell lines in vitro.
Zdravilo in vitro ni vplivalo na proliferacijo nehematoloških tumorskih celičnih linij.
4.2 Posology and method of administration.
4.2 Odmerjanje in način uporabe
You may remove your MIRCERA pre-filled syringe from the refrigerator and store it at a room temperature not above 30 °C for a single period of one month.
Napolnjeno injekcijsko brizgo zdravila MIRCERA lahko vzamete iz hladilnika samo enkrat in jo shranite pri sobni temperaturi do 30 °C za obdobje enega meseca.
In case PRCA is diagnosed, therapy with MIRCERA must be discontinued, and patients should not be switched to another recombinant erythropoietic protein (see section 4.4).
Če je diagnosticirana čista aplazija rdečih krvnih celic, je treba terapijo z zdravilom MIRCERA prekiniti, bolnika pa se ne sme prevesti na drugo rekombinantno eritropoetično beljakovino (glejte poglavje 4.4).
Slowly push the plunger with the thumb while holding the syringe with the forefinger and the middle finger against the finger grips until all the medicine is injected.
Bat počasi s palcem potiskajte navznoter, medtem ko injekcijsko brizgo držite s konicami kazalca in sredinca, dokler ne injicirate celotnega odmerka zdravila.
Name and address of the manufacturer responsible for batch release for the pre-filled syringes
Ime in naslov proizvajalca, odgovornega za sproščanje serij napolnjenih injekcijskih brizg Roche Pharma AG
The first MIRCERA dose will be given on the planned injection day of your previous medicine.
boste prejeli na dan, kot je bilo načrtovano dajanje vašega prejšnjega zdravila.
Stop using Mircera if you develop these symptoms and contact your doctor or seek medical attention immediately, see also section 2.
Če se pojavijo ti simptomi, prenehajte uporabljati zdravilo Mircera in nemudoma obvestite zdravnika ali poiščite zdravniško pomoč; glejte tudi poglavje 2.
The absolute bioavailability of methoxy polyethylene glycol-epoetin beta after subcutaneous administration was 54%.
Absolutna biološka uporabnost metoksipolietilenglikol epoetina beta je bila po subkutanem dajanju 54 %.
You will not receive another ESA and your doctor will treat you for this condition.
Drugih zdravil za spodbujanje eritropoeze ne boste prejeli, vaš zdravnik pa bo zdravil to stanje.
· Never attempt to take the syringe apart.
· Nikoli ne poskušajte injekcijske brizge razstaviti.
If you are on dialysis, the recommended starting dose is 0.6 micrograms for every kilogram of your body weight.
Če ste dializni bolnik, potem je priporočeni začetni odmerek 0,6 mikrograma na kilogram telesne mase.
No dose adjustment is required in patients aged 65 years or older.
Za bolnike, stare 65 let in več, prilagajanje odmerka ni potrebno.
Pulmonary embolism*
redki pljučni embolizem*
It can be injected subcutaneously in the abdomen, arm or thigh.
Lahko ga injiciramo sukbutano v trebuh, roko ali stegno.
Prefilled syringes 30, 50, 75 micrograms are available in pack size of 1 or 3 pre-filled syringe(s).
30-, 50- in 75-mikrogramske napolnjene injekcijske brizge so na voljo v pakiranjih z 1 ali 3 napolnjenimi injekcijskimi brizgami.
During treatment with MIRCERA
Med zdravljenjem z zdravilom MIRCERA
How to use MIRCERA
Kako uporabljati zdravilo MIRCERA
More severe cases have been observed with long-acting epoetins.At the time of prescription patients should be advised of the signs and symptoms and monitored closely for skin reactions.
Ob predpisu zdravila je treba bolnike seznaniti z znaki in simptomi kožnih reakcij in jih pozorno spremljati.
Peel back the protective film from the plastic tray and remove the needle and the syringe, holding the syringe by the middle of the body without touching the release clips.
Odlepite zaščitno folijo s plastičnega omota in vzemite ven injekcijsko brizgo ter iglo tako, da držite injekcijsko brizgo na sredini, brez da bi se dotaknili sprostitvenih sponk.
Do not inject into moles, scars, bruises, or areas where the skin is tender, red, hard or not intact.
brazgotine ali mesta, kjer je koža nežna, rdeča, trda ali poškodovana.
Grasp the packaged needle firmly in both hands.
Z obema rokama trdno primite iglo.
In patients with a poor haemoglobin response to epoetins, alternative explanations for the poor response should be considered (see section 4.2 and 5.1).
Pri bolnikih s slabim odzivom hemoglobina na epoetine je treba razmisliti o drugih razlagah za slab odziv (glejte poglavji 4.2 in 5.1).
In addition, using a panel of human tissues, the in vitro binding of methoxy polyethylene glycol-epoetin beta was only observed in target cells (bone marrow progenitor cells).
Pri uporabi plošče s humanimi tkivi so in vitro vezavo metoksipolietilenglikol epoetina beta opazili le pri tarčnih celicah (progenitorne matične celice kostnega mozga).
Your doctor may increase or decrease your dose or temporarily stop your treatment to adjust your haemoglobin to an appropriate level for you.
Zdravnik lahko poveča ali zmanjša odmerek ali pa začasno prekine zdravljenje, tako prilagodi koncentracijo hemoglobina, kot je za vas primerno.
MIRCERA should be administered either subcutaneously or intravenously.
Zdravilo MIRCERA dajemo subkutano ali intravensko.
• Your doctor will check the amount of iron in your blood before and during MIRCERA treatment.
· Zdravnik bo pred in med zdravljenjem z zdravilom MIRCERA preverjal količino železa v vaši krvi.